预约演示
更新于：2026-06-15
Fluocinolone Acetonide/Hydroquinone/Tretinoin
氟轻松丙酮酯/氢醌/维A酸
更新于：2026-06-15
概要
基本信息
药物类型 小分子化药 |
别名 Hydroquinone/tretinoin/fluocinolone-acetonide、Tri-Luma、孚立美 |
作用方式 激动剂、抑制剂 |
作用机制 GR激动剂(糖皮质激素受体激动剂)、RARα激动剂(维甲酸受体α激动剂)、RARβ2激动剂(维甲酸受体β激动剂) |
在研适应症 |
非在研适应症 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2002-01-18), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H30F2O6 |
InChIKeyFEBLZLNTKCEFIT-VSXGLTOVSA-N |
CAS号67-73-2 |
查看全部结构式(3)
关联
10
项与 氟轻松丙酮酯/氢醌/维A酸 相关的临床试验IRCT20220919055994N3
Evaluating the Effectiveness of Cispersa Cream Compared to Tri-luma Formulation in the Treatment of Melasma
CTR20244786
评价氟轻松氢醌维A酸乳膏治疗中、重度黄褐斑的疗效和安全性的多中心、随机、双盲、三臂、平行、安慰剂对照临床试验
CTRI/2024/10/075324
A split face study to compare efficacy and safety of Modified Kligman Formula (Hydroquinone 2% + Tretinoin 0.05% + Flucinolone Acetonide 0.01%) with Topical Metformin 30% in the patients with Melasma - A Prospective Comparative Study in Tertiary Care Hospital - NIL
100 项与 氟轻松丙酮酯/氢醌/维A酸 相关的临床结果
登录后查看更多信息
100 项与 氟轻松丙酮酯/氢醌/维A酸 相关的转化医学
登录后查看更多信息
100 项与 氟轻松丙酮酯/氢醌/维A酸 相关的专利（医药）
登录后查看更多信息
5
项与 氟轻松丙酮酯/氢醌/维A酸 相关的文献（医药）2026-05-01JAAD case reports
Near-complete clinical improvement of an extensive congenital acantholytic epidermal nevus treated with topical fluocinolone acetonide/hydroquinone/tretinoin (Tri-luma): A case report
Article
作者: Rivera Ocampo, Stefania
2025-05-01Journal of Cosmetic Dermatology
Efficacy and Safety of Generic Fluocinolone Acetonide, Hydroquinone, and Tretinoin Cream Compared With TRI‐LUMA for the Treatment of Moderate‐To‐Severe Melasma in Chinese Patients: A Randomized, Single‐Center, Placebo‐Controlled Trial
Article
作者: Lunfei Liu ; Chengyao Zhu ; Honghua Hu ; Hongliang Yao ; Pengfei Zhou ; Bo Shen ; Xiangke Yu ; Bo Feng
ABSTRACT:
Background:
Treatment with fluocinolone acetonide, hydroquinone, and tretinoin cream is the gold standard for melasma; however, the effects of this treatment in the Chinese population remain unclear. Due to the differences between Chinese and Caucasian subjects, further clinical trials in Chinese patients with melasma are needed.
Aim:
To evaluate the efficacy and safety of fluocinolone acetonide, hydroquinone, and tretinoin creams in Chinese patients with moderate‐to‐severe melasma.
Methods:
We recruited 53 patients who received a generic formulation (triple combination cream, TCC), brand formulation (TRI‐LUMA), or placebo once daily for 8 weeks. In weeks 4 and 8, efficacy was evaluated based on the Melasma Severity Scale and Melasma Area and Severity Index. In addition, safety was assessed based on the incidence and severity of treatment‐emergent adverse events.
Results:
The generic TCC group achieved 52.2% efficacy compared to 57.1% in the TRI‐LUMA group. There was no significant difference in the incidence of adverse effects between the TCC and TRI‐LUMA groups (69.6% and 90.5%, respectively; p > 0.05). The incidence of adverse events in the placebo group was 0%.
Conclusion:
Generic TCC was as effective as TRI‐LUMA and had a similar safety profile in this study of Chinese subjects with moderate‐to‐severe melasma.
2016-11-01Journal of drugs in dermatology : JDD4区 · 医学
The Efficacy of Q-Switched ND:YAG 1064 nm Laser in Recalcitrant Macular Amyloidosis: A Case Report.
4区 · 医学
Article
作者: Khurana, Nevil ; Urman, Christine
Macular amyloidosis typically presents as small, dusky-brown or greyish pigmented macules, the result of altered keratin deposition. Treatment of these hyperpigmented regions with topical and systemic therapies remains challenging, however Q-Switched neodymi- um-doped yttrium aluminum garnet (ND:YAG) laser has proven to be an effective treatment modality to reduce hyperpigmentation. In this case report we investigated the ef cacy of Q-Switched Nd:YAG laser treatment on a 34-year old woman with recalcitrant macular amyloidosis who failed to respond to over-the-counter bleaching creams. The patient was treated with 7 treatment sessions of Q- Switched Nd:YAG laser at one month intervals. According to our photographic analysis and patient self-assessment, the patient ap- peared to improve with each treatment session. Post-recurrence of the lesion after reaction to Triluma ( uocoinolone actetonide 0.01%, hydroquinone 4%, tretinoin 0.05%), the patient has been continuing to respond well to a second round of treatment with Q-switched Nd:YAG laser at 1064 nm. J Drugs Dermatol. 2016;15(11):1456-1458..
100 项与 氟轻松丙酮酯/氢醌/维A酸 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 黄褐斑 | 美国 | 2002-01-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 雀斑样痣 | 临床2期 | 智利 | - | 2008-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 50 | Cryotherapy (CRY-AC3® device)+Tri-luma (Group 1) | 選鏇艱網壓蓋壓鹹簾廠(齋鏇獵積憲鬱築憲鏇窪) = 積範鏇鏇膚鹽遞構範製 鏇選齋願醖積鑰顧網鹹 (構鹽襯鹹鹹膚鹽衊觸鏇, 7.0) 更多 | - | 2020-09-17 | ||
Cryotherapy (CRY-AC3® device) (Group 2) | 選鏇艱網壓蓋壓鹹簾廠(齋鏇獵積憲鬱築憲鏇窪) = 窪鏇鏇願壓窪網膚夢獵 鏇選齋願醖積鑰顧網鹹 (構鹽襯鹹鹹膚鹽衊觸鏇, 11.0) 更多 | ||||||
临床4期 | 56 | (Intense Pulsed Light (IPL) / Tri-Luma® Cream) | 鏇鏇鏇夢鹹繭構糧醖衊 = 顧顧鹽製夢鹽遞糧夢構 衊壓獵網夢觸窪衊糧淵 (繭醖築遞獵鑰淵鹹簾遞, 鹽繭膚艱網構鹽鹽齋鬱 ~ 夢餘夢顧鹽衊遞膚獵鬱) 更多 | - | 2010-01-11 | ||
Cetaphil (Intense Pulsed Light (IPL) / Inactive Control Cream) | 鏇鏇鏇夢鹹繭構糧醖衊 = 網餘衊憲憲繭窪糧獵築 衊壓獵網夢觸窪衊糧淵 (繭醖築遞獵鑰淵鹹簾遞, 鹹壓選獵齋製壓壓襯餘 ~ 憲蓋憲夢構獵簾膚築襯) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用